Abstract
We propose a novel formulation of a moving boundary method to account for the motion of the intimal flap (IF) in a TBAD post-thoracic endovascular aortic repair using patient-specific compliant computational fluid dynamics simulations. The simulations were informed by non-invasive 4DMRI sequences. Predicted flow waveforms, aortic wall and IF displacements were validated against in vivo 4DMRI and cine MRI data. The patient-specific simulation showed that at peak systole, the dynamic interplay between high IF displacement and high transmural pressures promoted true lumen compression and false lumen expansion, while luminal patterns were reversed at the deceleration phase. High vorticity and swirling flow patterns were observed throughout the cardiac cycle at the primary entry tear, the descending aorta and proximal to the visceral aortic branches, correlating with high relative residence time, which could indicate an increased localised risk of aortic growth proximal to the IF. A rigid IF simulation revealed significant discrepancies in haemodynamic metrics, highlighting the potential mispredictions when using a rigid wall assumption to assess disease progression. Simulations assuming a more compliant IF highlighted increased risks of visceral branches malperfusion and localised aortic wall degeneration. The study underscores the necessity of patient-specific-compliant IF simulations for accurate TBAD hemodynamic assessments. These insights can improve disease understanding and inform future treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We thank the Department of Mechanical Engineering at University College London, the Wellcome EPSRC Centre for Interventional Surgical Sciences (WEISS) (203145/A/16/Z), the British Heart Foundation (NH/20/1/34705), the Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) (BB/X005062/1) for their funding support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Cantonal Ethics Committee of Bern (Kantonale Ethikkommission für die Forschung), under the jurisdiction of the Gesundheits- und Fürsorgedirektion des Kantons Bern (Health and Welfare Directorate of the Canton of Bern). The approval reference number for this study is 2019-00556, and the decision of the comitee was issued on July 30, 2019.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
